Trial Profile
An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects With Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 27 Oct 2015 Results published in the Clinical Therapeutics
- 18 Dec 2013 New trial record